Knowledge HQ

Describes a 9-day protocol for generating CAR-T cells from rhesus macaque PBMCs. G-Rex 6-well plates were used for the expansion phase (days 5-9). The method produced high numbers of viable cells with a central memory phenotype suitable for infusion.

Report on a patient with metastatic colorectal cancer treated with TILs targeting a p53 mutation. TILs were screened and expanded using G-Rex 100. Although specific T-cells were identified, clinical response was limited due to loss of HLA heterozygosity in the tumor.

A Phase II study evaluating low-dose IL-2 with TILs for metastatic melanoma. 12 patients treated with non-myeloablative chemotherapy and TILs expanded in G-Rex100. Two partial responses and one unconfirmed PR were observed. Low-dose IL-2 was feasible but resulted in lower response rates compared to high-dose regimens.

A review of CAR T-cell process development challenges. It highlights G-Rex as an alternative to bags, capable of supporting high T-cell numbers (~20x10^9) and adaptable to automated harvesting systems.

This study enhanced NK cell bone marrow homing by transfecting them with a CXCR4 variant. NK cells were expanded ex vivo for 14-18 days in G-Rex with feeder cells, providing a robust platform for generating cells for genetic modification.

This study established an automated process for Treg expansion on the CliniMACS Prodigy. Manual expansion in G-Rex 100 and G-Rex 10 served as the standard control, showing comparable expansion kinetics and phenotype to the automated system.

The authors developed a streamlined manufacturing process for CAR-T cells performed entirely within G-Rex. This approach, including transduction in the G-Rex, reduced costs and labor while maintaining cell quality compared to bag-based methods.

This study validates leukoreduction system chambers as a source of PBMCs for T cell therapy. G-Rex culture vessels were used to generate and expand pathogen-specific T cell lines, showing they are equivalent to those derived from peripheral blood.

The study investigates combining BRAF inhibitors with TIL therapy for resistant melanoma. In the associated clinical trial, patient TILs were rapidly expanded in G-Rex, facilitating the combination therapy approach.

This Phase 1 trial demonstrated the safety of NKG2D CAR-T cells in hematologic cancers. G-Rex were used for the ex vivo expansion of CAR-T cells during the 9-day manufacturing process, ensuring sufficient cell yield for infusion.

A method to expand Vγ9Vδ2 T cells using engineered K562 aAPCs was optimized in G-Rex vessels. The G-Rex platform enabled the generation of large numbers of functional gamma-delta T cells suitable for CAR modification and allogeneic therapy.

This study evaluated G-Rex culture systems for producing megakaryocytes from CD34+ cells. G-Rex cultures with optimized seeding densities significantly increased the expansion of Mk progenitors and overall yield compared to standard tissue culture surfaces.